DxC 700 AU chem analyzer gets FDA clearance
April 3, 2017—Beckman Coulter Diagnostics announced the FDA clearance and U.S. commercial launch of its DxC 700 AU chemistry analyzer. The system brings together the design of the DxC analyzer and the throughput and workhorse capabilities of the AU analyzer into one standardized platform designed to meet the needs of mid- to high-volume clinical laboratories.
The analyzer reduces the number of test-processing steps by 30 percent, according to a company statement. The reduction in steps is the result of powerful operating software, an all-new design, and an intuitive user interface that aim to allow operators to spend less time on daily tasks and more time producing quality results.
The DxC 700 AU analyzer aims to reduce total cost of ownership by using fewer consumables compared with other industry same-class systems. The system uses concentrated reagents, long-lasting ion-selective electrodes, and nondisposable cuvettes.
The DxC 700 AU system is currently available in the U.S. and will be available in other regions of the world this year.